PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
Maria Kontaridis(Beth Israel Deaconess Medical Center), Benjamin G. Neel(NYU Langone Health)
Cited by 331
Related Papers
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
|Cancer Research|2023|102
Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines
|Journal of Clinical Investigation|2016|36
Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome
|Nature Communications|2017|25
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2020|14
Both Fallopian Tube and Ovarian Surface Epithelium Can Act as Cell-of-Origin for High Grade Serous Ovarian Carcinoma
|bioRxiv (Cold Spring Harbor Laboratory)|2018|10